The US Food and Drug Administration recently approved onasemnogene abeparvovec-xioi (Zolgensma, AveXis Inc, a Novartis company), the first gene therapy for children younger than age 2 who have spinal muscular atrophy.
The price tag for a one-time infusion: more than $2 million. This makes Zolgensma the world’s most expensive drug, although the company said it is working closely with insurers to create 5-year outcomes-based agreements and novel pay-over-time options. Divided over 5 years, the drug costs $425,000 per year.
Medscape Reader Polls © 2019
Cite this: Do You Consider Cost When Prescribing a Drug? – Medscape – Jun 12, 2019.